Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma

Unresectable hepatocellular carcinoma has several different therapeutic options, including targeted agents as well as locoregional therapy. Yttrium-90 (Y90) radioembolization therapy is an established treatment for unresectable disease and has been compared to other locoregional options as well as d...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabrinsky, Edward, James, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296880/
https://www.ncbi.nlm.nih.gov/pubmed/32550079
http://dx.doi.org/10.7759/cureus.8163
_version_ 1783546915507404800
author Nabrinsky, Edward
James, Edward
author_facet Nabrinsky, Edward
James, Edward
author_sort Nabrinsky, Edward
collection PubMed
description Unresectable hepatocellular carcinoma has several different therapeutic options, including targeted agents as well as locoregional therapy. Yttrium-90 (Y90) radioembolization therapy is an established treatment for unresectable disease and has been compared to other locoregional options as well as different targeted therapies. Newer case series are also reporting a potential benefit to the addition of immunotherapy to Y90 radioembolization. Here we report a case of prolonged survival in a patient whose treatment course included Y90 radioembolization along with sorafenib and nivolumab.
format Online
Article
Text
id pubmed-7296880
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-72968802020-06-16 Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma Nabrinsky, Edward James, Edward Cureus Radiation Oncology Unresectable hepatocellular carcinoma has several different therapeutic options, including targeted agents as well as locoregional therapy. Yttrium-90 (Y90) radioembolization therapy is an established treatment for unresectable disease and has been compared to other locoregional options as well as different targeted therapies. Newer case series are also reporting a potential benefit to the addition of immunotherapy to Y90 radioembolization. Here we report a case of prolonged survival in a patient whose treatment course included Y90 radioembolization along with sorafenib and nivolumab. Cureus 2020-05-16 /pmc/articles/PMC7296880/ /pubmed/32550079 http://dx.doi.org/10.7759/cureus.8163 Text en Copyright © 2020, Nabrinsky et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Radiation Oncology
Nabrinsky, Edward
James, Edward
Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
title Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
title_full Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
title_fullStr Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
title_full_unstemmed Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
title_short Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
title_sort highlighting survival with yttrium-90 radioembolization therapy in unresectable hepatocellular carcinoma
topic Radiation Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296880/
https://www.ncbi.nlm.nih.gov/pubmed/32550079
http://dx.doi.org/10.7759/cureus.8163
work_keys_str_mv AT nabrinskyedward highlightingsurvivalwithyttrium90radioembolizationtherapyinunresectablehepatocellularcarcinoma
AT jamesedward highlightingsurvivalwithyttrium90radioembolizationtherapyinunresectablehepatocellularcarcinoma

Ejemplares similares